CSL Biotherapies History.

Reliability — Safety — Quality — Heritage

CSL Biotherapies understands the influenza vaccine business and customers’ needs for reliable and safe flu vaccine supplies.

Millions of people outside the United States already rely on CSL for their flu vaccine. Our parent company, CSL Limited, operates one of the world’s largest influenza vaccine facilities for global markets in Melbourne, Australia and provides flu vaccine to Australia, New Zealand, and more than 16 countries in Europe, South America and Asia.

Beginning with the 2007-2008 season, CSL Biotherapies contributes to meeting the growing demand in the United States for reliable supplies of flu vaccine each year. CSL Biotherapies is ideally positioned to become a reliable resource for healthcare professionals who actively embrace the United States government’s flu immunization recommendations.

CSL Biotherapies will offer several competitive advantages to healthcare professionals in search of timely delivery of high-quality flu vaccines.

Product Registration Worldwide

Currently, CSL influenza vaccine is licensed in more than 20 countries worldwide. The product is known by various trade names in different markets, including Afluria^® Influenza Virus Vaccine, Enzira^®, Fluvax™, Nilgrip™, and X-Flu™.

For more information, please visit the CSL Biotherapies Website at:
www.cslbiotherapies-us.com.

Important Safety Information

Afluria^® is indicated for active immunization of persons 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria^®; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria^®.

Afluria^® should not be administered to individuals with hypersensitivity to eggs or chicken protein or other components of Afluria^®, or to anyone who has had a life-threatening reaction to previous influenza vaccination. The most common injection-site adverse reactions were tenderness, pain, redness, and swelling. The most common systemic adverse reactions were headache, malaise, and muscle aches.

Vaccination with Afluria^® may not protect all individuals. Immunocompromised persons may have a diminished immune response. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Afluria^® should be based on careful consideration of the potential benefits and risks.

Click here for full PRESCRIBING INFORMATION.